Minomic Archives - We are Minomic

Sydney Biotech Minomic International Ltd Strikes New Arrangement to Make MiCheck^® Prostate Test Available for Australians

by Minomic | Jun 23, 2022

Minomic International Ltd has taken a step forward to bring the MiCheck® Prostate test to Australians. MiCheck® Prostate detects aggressive prostate cancer overcoming the low accuracy of conventional screening tests, reducing unnecessary intervention such as painful...

Minomic International Ltd Celebrates US Lab Partnership at Ribbon Cutting Event

by Minomic | Jun 9, 2022

Minomic CEO Dr Brad Walsh and US Commercialisation Lead Megan Henken presented at its US lab partner 20/20 GeneSystems’ ribbon cutting event in Rockville, Maryland last week to celebrate the commencement of CLIAx’s operations. Last year 20/20 GeneSystems launched its...

Minomic Granted CLIA Certification Enabling Commercial Launch of MiCheck^® Prostate in the US

by Minomic | Apr 12, 2022

Minomic International Limited is pleased to announce that its wholly owned subsidiary, Minomic Inc., has been granted a Clinical Laboratory Improvement Amendments (CLIA) certification, allowing its lab to officially open for business, in Gaithersburg, MD. The CLIA...

Minomic International Limited appoints US Lab Director

by Minomic | Mar 10, 2022

Minomic is pleased to announce the appointment of Dr Chih-Ling Zao as its US Laboratory Director. Chih-Ling is an American Board of Bioanalysis certified high-complexity Laboratory Director with over ten years’ extensive diagnostic laboratory experience in the...

Minomic takes MiCheck^® Prostate to ASCO Genitourinary Cancers Symposium in San Francisco

by Minomic | Mar 2, 2022

Minomic International Limited recently attended the Genitourinary Cancers Symposium which was held in San Francisco and presented data from their latest study on the diagnostic test the company has developed to assist in the detection of aggressive prostate cancer....

Federal government funding to boost commercialisation of Minomic’s MiCheck^® Prostate

by Minomic | Feb 3, 2022

SYDNEY: Minomic International Ltd. is pleased to announce that it is the beneficiary of a tranche of co-investment from the Advanced Manufacturing Growth Centre’s (AMGC) Commercialisation Fund and the Federal Government’s Modern Manufacturing Initiative. One of 24...

« Older Entries

PUBLICATIONS

Phenotypic profiling of pancreatic ductal adenocarcinoma plasma-derived small extracellular vesicles for cancer diagnosis and cancer stage prediction: a proof-of-concept study. Wei Zhang, Ling Wang, Dan Li, Douglas H. Campbell, Bradley J. Walsh, et al. RSC. 2022.

Development and evaluation of the MiCheck test for aggressive prostate cancer. Shore ND, Pieczonka CM, Henderson RJ, Bailen JL, Saltzstein DR, Concepcion RS, et al. Urol Oncol Semin Orig Investig. 2020.

A comparison of prostate health index, total PSA, %free PSA, and proPSA in a contemporary US population—The MiCheck-01 prospective trial Shore ND, Pieczonka CM, Henderson RJ, Bailen JL, Saltzstein DR, Concepcion RS, et al. Urol Oncol. 2020.

The Role of Glypican-1 in the Tumour Microenvironment. Lund ME, Campbell DH, Walsh BJ. Adv Exp Med Biol. 2020.

Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer. Campbell DH, Lund ME, Nocon AL, Cozzi PJ, Frydenberg M, De Souza P, et al. PLoS One. 2018.

Development of a reliable assay to measure glypican-1 in plasma and serum reveals circulating glypican-1 as a novel prostate cancer biomarker. Levin RA, Lund ME, Truong Q, Wu A, Shore ND, Saltzstein DR, et al. Oncotarget. 2018.

Glypican-1 as a biomarker for prostate cancer: Isolation and characterization. Truong Q, Justiniano IO, Nocon AL, Soon JT, Wissmueller S, Campbell DH, et al. J Cancer. 2016.

PATENTS

Minomic Patent Estate

￼Sydney Biotech Minomic International Ltd Strikes New Arrangement to Make MiCheck® Prostate Test Available for Australians